GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » G Medical Innovations Holdings Ltd (FRA:9GM0) » Definitions » Intrinsic Value: Projected FCF

G Medical Innovations Holdings (FRA:9GM0) Intrinsic Value: Projected FCF : €0.00 (As of Jun. 24, 2024)


View and export this data going back to 2017. Start your Free Trial

What is G Medical Innovations Holdings Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-24), G Medical Innovations Holdings's Intrinsic Value: Projected FCF is €0.00. The stock price of G Medical Innovations Holdings is €0.068. Therefore, G Medical Innovations Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for G Medical Innovations Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:

FRA:9GM0's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.61
* Ranked among companies with meaningful Price-to-Projected-FCF only.

G Medical Innovations Holdings Intrinsic Value: Projected FCF Historical Data

The historical data trend for G Medical Innovations Holdings's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G Medical Innovations Holdings Intrinsic Value: Projected FCF Chart

G Medical Innovations Holdings Annual Data
Trend Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

G Medical Innovations Holdings Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of G Medical Innovations Holdings's Intrinsic Value: Projected FCF

For the Medical Instruments & Supplies subindustry, G Medical Innovations Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


G Medical Innovations Holdings's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, G Medical Innovations Holdings's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where G Medical Innovations Holdings's Price-to-Projected-FCF falls into.



G Medical Innovations Holdings Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



G Medical Innovations Holdings  (FRA:9GM0) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

G Medical Innovations Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.068/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


G Medical Innovations Holdings Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of G Medical Innovations Holdings's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


G Medical Innovations Holdings (FRA:9GM0) Business Description

Traded in Other Exchanges
N/A
Address
5 Oppenheimer Street, Rehovot, ISR, 7670105
G Medical Innovations Holdings Ltd is a mobile health (mHealth), telemedicine solutions, and monitoring service platforms. It develops and markets clinical and consumer medical-grade health monitoring solutions and offers end-to-end support for e-health projects. The company offers a suite of both consumer and clinical grade products and platforms which are positioned to reduce inefficiencies in healthcare delivery, improve access, reduce costs, increase the quality of care, and make healthcare more personalized and precise. Its operating segment includes Products, Patient Services, and Covid-19 testing. The company generates maximum revenue from the Patient Services segment.

G Medical Innovations Holdings (FRA:9GM0) Headlines

No Headlines